Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and tolerance of a single
administration of Pegfilgrastim in patients with lymphoma or myeloma receiving high-dose
chemotherapy and autologous peripheral stem cell support, and to estimate the costs incurred.
Eligible patients will be randomized. The estimated inclusion period is approximately 18
months. The duration of the research is 22 months. The maximum duration of participation for
each patient is 3 months.
The number of patients required in this multicentric and prospective study is 150 (13
participating centers).
This is a phase II, controlled, randomized, non comparative and open-label multicentric
study.